# US 2019/0315837 A1 · P97 fusion proteins

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0315837 A1
- Document ID: US20190315837A1
- Status: Published application
- Kind: A1
- Application number: 16/271,838
- Filed: 2019-02-10
- Published: 2019-10-17
- Earliest claimed: 2014-02-03
- Assignees: Bioasis Technologies, Inc.
- Applicants: Bioasis Technologies, Inc.
- Inventors: Timothy Z. Vitalis; Reinhard Gabathuler
- Web page: https://patentgrep.com/patent/US20190315837A1

## CPC

- C07K 14/79: Transferrins, e.g. lactoferrins, ovotransferrins
- A61K 39/39558: {against tumor tissues, cells, antigens}
- A61P 1/00: Drugs for disorders of the alimentary tract or the digestive system
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 35/00: Antineoplastic agents
- A61P 35/04: specific for metastasis
- C07K 16/32: against translation products of oncogenes
- A61K 2039/505: {comprising antibodies}
- C07K 2317/515: Complete light chain, i.e. VL + CL
- C07K 2317/732: Antibody-dependent cellular cytotoxicity [ADCC]
- C07K 2319/00: Fusion polypeptide
- C07K 2319/10: containing a tag for extracellular membrane crossing, e.g. TAT or VP22
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Provided are p97 (melanotransferrin)-trastuzumab fusion proteins and related methods of use thereof, for instance, to facilitate delivery of trastuzumab across the blood-brain barrier (BBB) and/or improve tissue penetration of the antibody in CNS and peripheral tissues, and thereby treat and/or diagnose HER2-positive cancers, including those of the central nervous system (CNS).

## Claims

### Claim 1

A fusion protein, comprising a trastuzumab heavy chain sequence comprising the amino acid sequence of SEQ ID NO:29 fused to the N-terminus or the C-terminus of a peptide fragment comprising an amino acid sequence at least 80% identical to DSSHAFTLDELR (SEQ ID NO: 14) and an optional linker in between, wherein the fusion protein binds to the human Her2/neu receptor.

### Claim at position 2

2-64. (canceled)

### Claim 65 (depends on 1)

The fusion protein of claim 1, wherein the fusion protein has ability to cross the blood-brain barrier.

### Claim 66 (depends on 1)

The fusion protein of claim 1, wherein the linker is a Gly, Ser and/or Asn-containing linker.

### Claim 67 (depends on 1)

The fusion protein of claim 1, further comprising a trastuzumab light chain sequence having the amino acid sequence of SEQ ID NO:36.

### Claim 68 (depends on 1)

A method for the treatment of a HER2-overexpressing cancer in a subject having a HER2-overexpressing cancer, comprising administering to the subject a fusion protein of claim 1.

### Claim 69 (depends on 68)

The method of claim 68 where the HER2-overexpressing cancer is at risk for metastasizing to the CNS of the subject, or has metastasized to the CNS of the subject.

### Claim 70 (depends on 69)

The method of claim 69, where the HER2-overexpressing cancer is HER2-overexpressing metastatic breast cancer, HER2-overexpressing metastatic gastric gastroesophageal junction adenocarcinoma, or HER2-overexpressing uterine serous carcinoma.

### Claim 71 (depends on 69)

The method of claim 69, wherein the treatment is part of an adjuvant treatment for a HER2-overexpresssing breast cancer.

### Claim 72 (depends on 71)

The method of claim 71, wherein the adjuvant treatment comprises the administration of doxorubicin, cyclophosphamide, and either paclitaxel or docetaxel.

### Claim 73 (depends on 72)

The method of claim 72, wherein the adjuvant treatment comprises the administration of docetaxel and carboplatin.

### Claim 74 (depends on 1)

A pharmaceutical composition comprising the fusion protein of claim 1 and a pharmaceutically acceptable carrier.
